Literature DB >> 10581232

Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies.

L Vergani1, M Barile, C Angelini, A B Burlina, L Nijtmans, M P Freda, C Brizio, E Zerbetto, F Dabbeni-Sala.   

Abstract

Two unrelated adult males, aged 36 (patient 1) and 25 (patient 2) years, presented with subacute carnitine-deficient lipid storage myopathy that was totally and partly responsive to riboflavin supplementation in the two patients, respectively. Plasma acyl-carnitine and urinary organic acid profiles indicated multiple acyl coenzyme A dehydrogenase deficiency, which was mild in patient 1 and severe in patient 2. The activities of short-chain and medium-chain acyl coenzyme A dehydrogenases in mitochondrial fractions were decreased, especially in patient 2. This was in agreement with Western blotting results. Flavin-dependent complexes I and II were studied by immunoblotting and densitometric quantification of two-dimensional electrophoresis with comparable results. Complex I was present in normal amounts in both patients, whereas complex II was decreased only in the pretherapy muscle of patient 2. Flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) concentrations in muscle and isolated mitochondria, and the activity of mitochondrial FAD pyrophosphatase, showed that patient 1 had low levels of FAD (46%) and FMN (49%) in mitochondria, with a significant increase (P < 0.01) in mitochondrial FAD pyrophosphatase (273%) compared with controls. Patient 2 had similar low levels of FAD and FMN in both total muscle (FAD and FMN 22% of controls) and mitochondria (FAD 26%; FMN 16%) and normal activity of mitochondrial FAD pyrophosphatase. All of these biochemical parameters were either totally or partly corrected after riboflavin therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10581232     DOI: 10.1093/brain/122.12.2401

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  20 in total

Review 1.  Advances in genetics: what are the benefits for patients?

Authors:  A Munnich
Journal:  J Med Genet       Date:  2005-12-09       Impact factor: 6.318

Review 2.  Riboflavin transport and metabolism in humans.

Authors:  Maria Barile; Teresa Anna Giancaspero; Piero Leone; Michele Galluccio; Cesare Indiveri
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

3.  Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.

Authors:  Karen M McCammon; Satya P Panda; Chuanwu Xia; Jung-Ja P Kim; Daniela Moutinho; Michel Kranendonk; Richard J Auchus; Eileen M Lafer; Debashis Ghosh; Pavel Martasek; Rekha Kar; Bettie Sue Masters; Linda J Roman
Journal:  J Biol Chem       Date:  2016-08-05       Impact factor: 5.157

4.  Molecular analysis of 51 unrelated pedigrees with late-onset multiple acyl-CoA dehydrogenation deficiency (MADD) in southern China confirmed the most common ETFDH mutation and high carrier frequency of c.250G>A.

Authors:  Zhi-Qiang Wang; Xue-Jiao Chen; Shen-Xing Murong; Ning Wang; Zhi-Ying Wu
Journal:  J Mol Med (Berl)       Date:  2011-02-24       Impact factor: 4.599

Review 5.  From cholesterogenesis to steroidogenesis: role of riboflavin and flavoenzymes in the biosynthesis of vitamin D.

Authors:  John T Pinto; Arthur J L Cooper
Journal:  Adv Nutr       Date:  2014-03-01       Impact factor: 8.701

6.  Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency.

Authors:  R K J Olsen; M Pourfarzam; A A M Morris; R C Dias; I Knudsen; B S Andresen; N Gregersen; S E Olpin
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

7.  Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.

Authors:  Pilar Gonzalez-Cabo; Sheila Ros; Francesc Palau
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

8.  The TP0796 lipoprotein of Treponema pallidum is a bimetal-dependent FAD pyrophosphatase with a potential role in flavin homeostasis.

Authors:  Ranjit K Deka; Chad A Brautigam; Wei Z Liu; Diana R Tomchick; Michael V Norgard
Journal:  J Biol Chem       Date:  2013-02-27       Impact factor: 5.157

9.  Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease.

Authors:  Juan Garrido-Maraver; Mario D Cordero; Irene Domínguez Moñino; Sheila Pereira-Arenas; Ana V Lechuga-Vieco; David Cotán; Mario De la Mata; Manuel Oropesa-Ávila; Manuel De Miguel; Juan Bautista Lorite; Eloy Rivas Infante; Manuel Alvarez-Dolado; Plácido Navas; Sandra Jackson; Silvia Francisci; José A Sánchez-Alcázar
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

10.  Mitochondrial fatty acid oxidation defects--remaining challenges.

Authors:  Niels Gregersen; Brage S Andresen; Christina B Pedersen; Rikke K J Olsen; Thomas J Corydon; Peter Bross
Journal:  J Inherit Metab Dis       Date:  2008-10-07       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.